Welcome to the Highlights from ASH 2013 Resource Center. This is your central portal for information presented at the 2013 ASH Annual Meeting in New Orleans, including novel treatment options, breaking clinical trials and guideline updates. Also featured are onsite video interviews with leading experts to get their reactions on some of the clinical updates and news presented at the conference, and what implications they have for the future.


Brentuximab vedotin induced long-term remissions in Hodgkin’s lymphoma

Ajay Gopal, MD 

Ajay K. Gopal

NEW ORLEANS — Half of patients with relapsed or refractory Hodgkin’s lymphoma who were treated with brentuximab vedotin were alive at 3 years, according to results of a phase 2 study presented at the ASH Annual Meeting and Exposition.

“The most interesting finding is that about 10% of patients on this trial have been off therapy and are enjoying long-term remissions,” Ajay K. Gopal, MD, associate professor at the University of Washington, a member of Fred Hutchinson Cancer Research Center and director of clinical research in hematologic malignancies at the Seattle Cancer Care Alliance, told HemOnc Today. “This raises the question that this agent may have curative potential in a subset of patients and sets the stage for formally evaluating this agent as part of initial therapy.” More »


Featured News